methods of birth control throughout the period of their 
involvement in this clinical research study. 
5. POTENTIAL BENEFITS: The use of the marked cells to identify 
the sources of relapse may be of benefit to patients on future 
protocols but this research will not be of immediate benefit 
to patients currently entering this trial. The major benefit 
is to patients in the future who are participating in this 
study. The evaluation of the contribution of the peripheral 
blood versus the bone marrow will help in the design of the 
bone marrow and peripheral blood. 
6. ALTERNATE PROCEDURES OR TREATMENTS: Participation in this 
marking study is totally optional and the treatment on 
autologous transplant protocols may be carried out whether or 
not patients participate in the marking study. The patient 
may decline to have marking but still have the bone marrow or 
peripheral blood transplant of his or her own cells. 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an oppprtunity to ask any questions 
concerning the investigational regimen involved and the 
investigator has willingly replied to my inquiries. This 
investigational treatment program will be administered under 
the above numbered, titled and described clinical research 
protocol at this institution. I hereby authorize Dr. 
, the attending physician/ investigator and 
designated associates to administer this investigational 
treatment program. 
8. I have been told and understand that my participation is 
voluntary. I may decide not to participate, or withdraw my 
consent and discontinue my participation at any time. Such 
action will be without prejudice and there shall be no penalty 
or loss of benefits to which I may otherwise be entitled, and 
I will continue to receive treatment by my physician at this 
institution. 
Should I decide not to participate or withdraw my consent from 
participation in this clinical research, I have been advised 
that I should discuss the consequences or effects of my 
decision with my physician. 
In addition, I understand that the investigator may 
discontinue the clinical research study if, in the sole 
opinion and discretion of the investigator, the study or 
treatment offers me little or no future benefit, or the supply 
of medication ceases to be available or other causes prevent 
continuation of the clinical research study. The investigator 
will notify me should such circumstances arise and my 
physician will advise me about available treatment which may 
be of benefit at that time. 
[876] 
Recombinant DNA Research, Volume 15 
